A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency

Descrizione del progetto

Un semplice trattamento ambulatoriale per la malattia da reflusso acido

La malattia del reflusso gastroesofageo è un disturbo del sistema digestivo provocato da difetti nello sfintere esofageo inferiore che causa bruciore di stomaco, rigurgito e reflusso di acido gastrico ed enzimi digestivi. Molto comune nell’Unione europea, questa condizione viene trattata attualmente con farmaci sintomatici, che non affrontano la causa sottostante. Il progetto, finanziato dall’UE, si propone di introdurre un trattamento ambulatoriale minimamente invasivo per questa malattia, con l’utilizzo di un agente di carica iniettabile al fine di supportare il rimodellamento endoscopico dello sfintere, per una cura a lungo termine. La procedura coinvolgerà l’iniezione di microsfere in polimetilmetacrilato biocompatibili, volta a fornire un substrato per la crescita di tessuto fibrovascolare nell’area interessata. La prima fase del progetto stabilirà la strategia commerciale e la bozza del piano di sviluppo.

Obiettivo

Gastroesophageal Reflux Disease (GERD) is a digestive disorder associated with symptoms such as heartburn and regurgitation, and reflux of normal gastric content like gastric acid and digestive enzymes. GERD is caused by a loss of integrity of the gastro-esophageal barrier known as the 'lower esophageal sphincter' (LES). This condition is one of the most common gastroenterological diagnosis in the European Union, with an estimated 15-20 Million daily sufferers. GERD today is typically treated with medications such as proton pump inhibitors (PPIs). Unfortunately, these anti-acid medications only ‘mask’ GERD symptoms, cause severe side-effects long-term, and about 20% of patients are non-responders. Importantly, they do not treat/cure the underlying root cause of acid reflux. For people who have severe GERD and do not respond to
medication, invasive surgical intervention remains the only option. G125 is the least invasive outpatient treatment for Gastroesophageal Reflux Disease (GERD). It is a permanent injectable bulking agent for the endoscopic treatment which enables cell growth in the Lower Esophagal Sphincter (LES), thereby providing long term cure for the debilitating symptoms of GERD. G125 uses a tissue-friendly (biocompatible) microspheres made of Polymethylmethcrylate (PMMA) suspended in
bovine collagen and an Elongated Flexible Syringe (EFS) which consists of an elongated catheter and a transition bore needle. The PMMA microspheres provide a permanent scaffold for stimulated fibro-vascular tissue ingrowth in the affected area. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further
development plan will be drafted. Within the overall innovation project AscentX Medical will refine the endoscopic injection procedure, perform a 12 month clinical trial with 60 patients followed by a scale up of the production to prepare for commercialization.

Campo scientifico

Programma(i)

Argomento(i)

EIC-SMEInst-2018-2020 - SME instrument

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

ASCENTX MEDICAL EUROPE LIMITED

Contribution nette de l'UE

€ 50 000,00

Indirizzo

UNIT 6 QUEENS YARD, WHITE POST LANE
E95EN LONDON
Regno Unito

PMI

Sì

Regione

London Inner London — West Camden and City of London

Tipo di attività

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Collegamenti

Contatta l’organizzazione

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Costo totale

€ 71 429,00